Navigation Links
New transdermal SARM drug for muscle-wasting offers hope for older cancer patients
Date:6/24/2014

CHICAGO, ILMuscle wasting that occurs as a result of cancer negatively impacts the well-being and recovery prospects of millions of patients, particularly the rapidly-growing elderly populations in Western societies. Drugs called selective androgen receptor modulators (SARMs) offer hope for these patients, and a new SARM for transdermal administration is promising excellent efficacy without harming liver function and HDL levels. Results and conclusions were presented Tuesday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

SARMs are able to stimulate the growth of muscle with effects similar to those seen by use of traditional anabolic steroids but without the undesirable side effects of those established muscle-building drugs, in particular, the adverse effects on prostate health that can occur from their use.

There are several SARMs currently in human clinical trials, with successful animal studies having already been conducted with these compounds. However, all of these drug candidates have been developed for oral administration. Because of potential adverse effects on liver function and on depression of HDL levels (the "good" cholesterol), the orally-administered drugs suffer limitations to their full therapeutic potential to grow muscle and strengthen bone.

A similar situation for oral delivery exists in the administration of male hormone therapy. Here, the adverse impacts on liver health and HDL levels can be overcome by the use of skin patches or gel that release a drug directly into the body through the skin, i.e., transdermal application. Recognizing the similarity, scientists at the pharmaceutical company Novartis therefore developed a SARM specifically for transdermal administration. In describing their drug candidate, AUSRM-057, Senior Investigator Dr. Hans-Joerg Keller of the Novartis Institutes for BioMedical Research, Basel, Switzerland said, "AUSRM-057 is the first SARM with excellent skin permeation properties which may exploit the full therapeutic potential of SARMs."

In this preclinical drug discovery project, Novartis researchers used classical techniques of drug development, first identifying a compound with good potential as a muscle-building drug in cell culture. Skin permeation tests, also conducted in cell culture, predicted that their drug candidate would show good penetration of skin in transdermal delivery. The drug did work as predicted in building muscle when tested in rats and did not show the masculinizing effects of SARMs that can harm the prostate gland. The authors are optimistic regarding the prospects of this drug candidate to become the first in its class to utilize not only the advantages SARMs have displayed for muscle growth without negative impacts on prostate health, but, by avoiding the digestive system, to also avoid adverse effects on liver function and HDL levels.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. New study offers potential avenues for treatment of deadly nasopharyngeal cancer
2. Study offers evidence that sunscreen use in childhood prevents melanoma in adults
3. New report offers a primer for doctors use of clinical genome and exome sequencing
4. Liquid biopsy offers new way to track lung cancer
5. Molecule linked to aggressive pancreatic cancer offers potential clinical advances
6. NIDA offers tools for talking to teens about marijuana
7. Extended-release medication offers promise for treating alcohol, opioid dependence
8. Mouse study offers new clues to cognitive decline
9. Breath analysis offers non-invasive method to detect early lung cancer
10. Review offers insight on managing surgical patients who are taking new drugs to prevent blood clots
11. New high-detail atlas offers tool to explore local environment and health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... "Success Files," a short- ... Alzheimer’s. Alzheimer’s is a disease estimated to affect the lives of more than ... the Alzheimer’s Association, a leading voice in the fight for cure and research ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly released app Smart ... to Smart Mart, customers can now order vegetable, fruit, snacks, dairy, or any ... find clothing at discounted prices. Apart from this, Smart Mart has emphasized upon ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic ... Florida is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as ... is an annual award that was started in 2003 to salute young achievers ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of ... can get while staying in compliance with FDA rules. , The FDA has ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... right or exercise more try taking a more holistic approach and use natural ... new Amazon essential oil collection is certified USDA guaranteeing that, the new line ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
Breaking Medicine Technology: